Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).

被引：0
|
作者：
Issa, Ghayas C.
Kantarjian, Hagop M.
Ravandi, Farhad
Thomas, Deborah A.
Khouri, Maria
Garcia-Manero, Guillermo
Garris, Rebecca S.
Cortes, Jorge E.
Short, Nicholas James
Sasaki, Koji
Schroeder, Heather M.
Kadia, Tapan M.
Verstovsek, Srdan
Daver, Naval Guastad
Jain, Nitin
Konopleva, Marina
O'Brien, Susan Mary
Jabbour, Elias
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7042
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia
    Yilmaz, Musa
    Kantarjian, Hagop
    Ravandi, Farhad
    Thomas, Deborah
    Khouri, Maria
    Garcia-Manero, Guillermo
    Garris, Rebecca
    Cortes, Jorge
    Short, Nicholas
    Sasaki, Koji
    Issa, Ghayas
    Koller, Paul
    Schroeder, Heather
    Kadia, Tapan
    Verstovsek, Srdan
    Daver, Naval
    Jain, Nitin
    Konopleva, Marina
    O'Brien, Susan
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S185 - S185
  • [2] Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL)
    Jabbour, Elias
    Hagop, Kantarjian
    Thomas, Deborah
    Garcia-Manero, Guillermo
    Hoehn, Daniela
    Garris, Rebecca
    Faderl, Stefan H.
    Cortes, Jorge E.
    Kadia, Tapan M.
    Ravandi, Farhad
    Verstovsek, Srdan
    O'Brien, Susan
    BLOOD, 2013, 122 (21)
  • [3] Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab As Frontline Therapy for Adults with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    Sasaki, Koji
    Garcia-Manero, Guillermo
    Garris, Rebecca
    Cortes, Jorge E.
    Kadia, Tapan M.
    Ravandi, Farhad
    Verstovsek, Srdan
    O'Brien, Susan
    BLOOD, 2014, 124 (21)
  • [4] Frontline Ofatumumab with Hyper-CVAD in CD20+Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
    Maiti, Abhishek
    Kantarjian, Hagop
    Ravandi, Farhad
    Thomas, Deborah
    Khouri, Maria
    Garcia-Manero, Guillermo
    Garris, Rebecca
    Cortes, Jorge
    Short, Nicholas
    Sasaki, Koji
    Issa, Ghayas
    Koller, Paul
    Schroeder, Heather
    Kadia, Tapan
    Verstovsek, Srdan
    Daver, Naval
    Jain, Nitin
    Konopleva, Marina
    O'Brien, Susan
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S256 - S257
  • [5] Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial
    Maiti, Abhishek
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Khouri, Maria
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Garris, Rebecca
    Cortes, Jorge E.
    Short, Nicholas J.
    Jain, Nitin
    Bose, Prithviraj
    Verstovsek, Srdan
    Konopleva, Marina
    Sasaki, Koji
    Issa, Ghayas C.
    Ghosn, Marie
    Schroeder, Heather M.
    Kadia, Tapan
    Daver, Naval
    O'Brien, Susan M.
    Jabbour, Elias J.
    BLOOD, 2017, 130
  • [6] A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+acute lymphoblastic leukemia (ALL): Updated results.
    Bazarbachi, Abdul Hamid
    Yilmaz, Musa
    Ravandi, Farhad
    Thomas, Deborah A.
    Khouri, Maria
    Garcia-Manero, Guillermo
    Garris, Rebecca S.
    Cortes, Jorge E.
    Short, Nicholas James
    Sasaki, Koji
    Issa, Ghayas C.
    Koller, Paul B.
    Kadia, Tapan M.
    Verstovsek, Srdan
    Daver, Naval Guastad
    Jain, Nitin
    Konopleva, Marina
    O'Brien, Susan Mary
    Jabbour, Elias
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)
    Sasaki, Koji
    Koller, Paul B.
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    Khouri, Maria R.
    Garcia-Manero, Guillermo
    Garris, Rebecca
    Cortes, Jorge E.
    Schroeder, Heather
    Chahoud, Jad
    Kadia, Tapan
    Ravandi, Farhad
    Verstovsek, Srdan
    Daver, Naval
    Jain, Nitin
    Konopleva, Marina
    O'Brien, Susan
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [8] Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL.
    Jabbour, Elias
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Aad, Simon Abi
    Garris, Rebecca
    Cortes, Jorge E.
    Kadia, Tapan M.
    Ravandi, Farhad
    Verstovsek, Srdan
    O'Brien, Susan Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Updated results of frontline ofatumumab-hyper-CVAD in adults with CD20+acute lymphoblastic leukemia.
    Maiti, Abhishek
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Thomas, Deborah A.
    Khouri, Maria
    Garcia-Manero, Guillermo
    Garris, Rebecca S.
    Cortes, Jorge E.
    Short, Nicholas James
    Sasaki, Koji
    Issa, Ghayas C.
    Koller, Paul B.
    Schroeder, Heather M.
    Kadia, Tapan M.
    Verstovsek, Srdan
    Daver, Naval Guastad
    Jain, Nitin
    Konopleva, Marina
    O'Brien, Susan Mary
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial
    Sasaki, Koji
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Daver, Naval
    Kadia, Tapan M.
    Khouri, Rita B.
    Alvarado, Yesid
    Burger, Jan A.
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Short, Nicholas J.
    Schroeder, Heather
    Garris, Rebecca
    Bose, Prithviraj
    Jain, Nitin
    Naqvi, Kiran
    Wierda, William G.
    Verstovsek, Srdan
    Cortes, Jorge E.
    Konopleva, Marina
    O'Brien, Susan M.
    Jabbour, Elias J.
    BLOOD, 2016, 128 (22)
12345